Top UK and international marketers honoured
NICE backs Sanofi's Aubagio for MS
Lilly pulls plug on antidepressant edivoxetine
Novartis' panobinostat impresses in myeloma trial
Europe okay for AstraZeneca's Fluenz Tetra
Seventeen months ago in the wake of the failure of schizophrenia drug pomeglumetad,
set out just how reliant Eli Lilly was on near-term R&D success. With the failure...
In some ways the astonishing 68% surge in the valuation of Puma Biotechnology yesterday – adding almost $1bn to the company’s market value – was predictable. A press release stating that its...
Almirall to lay off 250 staff in Spain
GSK consortium with six renowned cancer centres
Cegedim analysis shows worth of quality database